Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS Mutation

NCT03829410 is registered in ClinicalTrials.gov with Cardiff Oncology as lead sponsor.

NCT NCT03829410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03829410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS Mutation
Lead sponsor
Cardiff Oncology
Phase
Phase 1/2
Overall status
Completed
Start date
June 24, 2019
Completion date
January 29, 2024
Enrollment
68 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

kras gene mutation, metastatic colorectal cancer